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a  b  s  t  r  a  c  t
A  64-year-old  woman  with  recurrent  mitral  valve  stenosis  was  hospitalized  30 years  after  open  commis-
surotomy.  Severe  right  cerebral  embolism  occurred  at age  58, with  left  hemiparesis.  She was  debilitated
with  cardiac  cachexia.  Based  on  symptomatic  valvular  disease  ﬁndings,  surgery  was  considered,  but
deemed  too  high  risk  due  to the combined  insufﬁciencies.  She  refused  this  surgical  operation  and
requested  conservative  therapy.  Optimized  medication  and  cardiac  rehabilitation  improved  her  gen-
eral  condition  allowing  transfer  to another  hospital.  We  explained  the  short  life  expectancy  both  to  her
and  to her  family.  They  decided  to  transfer  to a hospice  at a  chronic  care  hospital  and  she was  given best
supportive  care. Eventually,  her urine  output  decreased  and  respiration  deteriorated.  She and  her  family
refused  resuscitation  in  the  event  of  cardiopulmonary  arrest,  requesting  only  suffering  reduction.  Thus,
continuous  intravenous  infusion  of  morphine  was  started.  The  optimized  doses  for pain  alleviation  were
determined  in  consultation  with  palliative  care  specialists  and  maximized  her  consciousness  level  for
the last  four  days.
“Heart-failure  hospice”  is  potentially  a place  to die  for  end-of-life  patients,  attended  by their  families
and  healthcare  providers.  They  need  prognostic  information  and  options  for  end-stage.  Our  experi-
ence  conﬁrms  results  about  palliative  care  from  previous  studies  conducted  overseas  demonstrating
the  effectiveness  of  opioids  relieving  end-stage  symptoms.
<Learning  objective:  Perform  an  appropriate  end-of-life  assessment  for  patients  with  irreversible  severe
heart failure.  Formulate  appropriate  plans  for further  evaluation  and  management,  including  referral  and
consultation  to  palliative  care  specialists  when  necessary.  Develop  an  appropriate  regional  cooperation,
with  consideration  given  to  the less  common  optional  treatment  for cardiac  dysfunction,  “heart-failure
3  Jap
hospice.”>
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Patients with chronic heart failure (CHF) are increasing in devel-
ped countries with aging populations [1]. Although advances in
reatment have prolonged survival, CHF becomes terminal after
epeated remissions and exacerbations. Patients and caregivers
ace challenging issues including quality of life and end-of-life
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CHF management. Standardizing CHF treatment is difﬁcult due
to background diversity. Moreover, because determining whether
CHF is end-stage is difﬁcult for healthcare providers, clinical
decisions about therapeutic aggressiveness are challenging. Thus,
life-prolonging invasive intervention is often continued, despite
end-stage CHF. One-year survival is reportedly ≤50% in New York
Heart Association (NYHA) class III/IV patients, a prognosis simi-
lar to that of stage IIIA lung cancer patients [2,3]. However, CHF
patients and families often do not recognize this poor progno-
sis. Patients with little long-term survival potential should receive
symptom-palliating treatment ﬁrst, with hospice care with opioids
for dyspnea among the options [4]. Patients and families need pro-
gnostic information and treatment options for end-stage CHF, with
treatment decisions being made cooperatively.
vier Ltd. All rights reserved.
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Table 1
Laboratory data on admission.
Peripheral blood Prothrombin time 42%
WBC  6180/l  Uric acid 6.5 mg/dl
RBC 315 × 104/l Total cholesterol 154 mg/dl
Hemoglobin 6.7 g/dl HDL cholesterol 55 mg/dl
Platelets 23.7 × 104/dl LDL cholesterol 96.0 mg/dl
Biochemistry Triglyceride 73 mg/dl
AST 16 IU/L Urinalysis
ALT 24 IU/L Protein (–)
LDH 202 IU/L Glucose (–)
ALP 380 IU/L Ketone body (–)
-GTP 24 IU/L Urobilinogen Normal
Total bile acids 1.0 mg/dl Sediment
CPK 22 IU/L RBC 1–4/HPF
Blood urea nitrogen 13.6 mg/dl WBC  0/HPF
Creatinine 0.52 mg/dl Casts (–)
Total protein 7.0 g/dl Relative density 1.005
Albumin 3.9 g/dl pH 8.0
Sodium 125 mEq/L
Potassium 4.1 mEq/L
Chloride 87 mEq/L
Fe 12 g/dl
Ferritin 8.3 ng/ml
NT-proBNP 1063 pg/ml
WBC, white blood count; RBC, red blood count; AST, aspartate amino transferase;
ALT, alanine amino transferase; LDH, lactate dehydrogenase; ALP, alkaline phos-
phine via a syringe pump was started. The optimized doses for pain
alleviation were determined in consultation with a palliative care
specialist (Fig. 5). Pain management maximized her consciousness6 T. Kisaka et al. / Journal of C
Estimated 70,000–100,000 CHF patients live in Hiroshima pre-
ecture. The Heart Failure Center of Hiroshima University Hospital
lays a central role in promoting a regional heart failure-following
etwork system by multiple medical facilities. Herein, we report a
atient with end-stage CHF, receiving optimized care at our hos-
ital and transferred to hospice at a regional medical facility with
onsent.
ase report
A 64-year-old woman underwent open commissurotomy for
itral valve stenosis at age 34 years. Severe right cerebral embolism
ccurred at age 58, with left hemiparesis caused by large cere-
ral infarction (Fig. 1). Echocardiography revealed recurrent mitral
alve stenosis, moderate aortic valve stenosis, severe secondary tri-
uspid valve regurgitation, and signiﬁcant right heart dilatation.
he refused reoperation, despite being a surgical candidate, and
ontinued medical treatment at a nearby clinic.
Anorexia, emaciation (height 150 cm,  weight 33 kg), and hepa-
omegaly developed in November 2011. By December, she was
ebilitated with cardiac cachexia and orthopnea. Compromised
ctivity prompted admission to our hospital in February 2012
Table 1). She had NYHA class III heart failure with impaired activ-
ties of daily living/quality of life status (Table 2), cardiomegaly
cardiothoracic ratio, 0.79), and increased pulmonary vessel shad-
ws. Echocardiography revealed decreased left ventricular wall
otion (left ventricular ejection fraction, 46%), severe aortic valve
tenosis (aortic valve area, 0.9 cm2; maximum velocity, 4 m/s), and
evere mitral valve stenosis (mitral valve area, 1.0 cm2) with sec-
ndary right heart failure (tricuspid pressure gradient, 41 mmHg)
Figs. 2 and 3). Based on symptomatic valvular disease ﬁndings at
er age, surgery was considered, but deemed too high risk due
o the combined valvular diseases. She and her family requested
onservative treatment. Doses of diuretic agents were optimized,
ncreasing urine output and ameliorating dyspnea. Cardiac reha-
ilitation with indoor walking was started despite paresis and
ehabilitation for cerebral infarction was also performed to prevent
ontractures and improve dysarthria (Table 3).
In April 2012, her general condition improved, allowing transfer
o another hospital. We  explained the poor prognosis and short
ife expectancy to the patient and her family. They requested con-
inuation of conservative therapy. The patient was thus referred
or follow-up to a facility near her home. Transfer was scheduled
o another chronic care facility following admission to a nearby
eneral hospital. At the general hospital, she was favorably treated
Fig. 1. Head computed tomography revealed cerebral infarction at onset.phatase; -GTP, -glutamyltransferase; CPK, creatine phosphokinase; Fe, iron;
NT-proBNP, N-terminal pro-B-type natriuretic peptide; HDL, high density lipopro-
tein; LDL, low density lipoprotein; HPF, high power ﬁeld; pH, potential of hydrogen.
for CHF and lumbago in May  2012. Urine output and edema were
controlled with thiazide diuretics (Fig. 4). She was  transferred
to hospice at a chronic care hospital near her home in mid-June
2012. She was given a mildly salt-restricted, adjusted for edema,
high-calorie and high-protein diet. She received appropriate
supplements when anorexia worsened. In early July 2012, her
respiratory state deteriorated after preceding oliguria. She and her
family again refused resuscitation in the event of cardiopulmonary
arrest, requesting only suffering reduction. Thus, palliative care
with opioids was  started: continuous intravenous infusion of mor-Table 2
Functional Independence Measure (FIM) score.
Self-care Communication and psychosocial
Eating 6 Expression 6
Grooming 2 Comprehension 6
Bathing/showering 2 Social interaction 5
Dressing upper body 2
Dressing lower body 2
Toileting 4
Mobility Cognition
Transfers: bed/chair/wheelchair 4 Problem solving 5
Transfers: toilet 4 Memory 5
Transfers: bathtub/shower 2
Locomotion: walking/wheelchair 4
Locomotion: stairs 1
Seven levels for each item.
Level description:
7  Complete independence, fully independent.
6  Modiﬁed independence, requiring the use of a device but no physical help.
5  Supervision, requiring only standby assistance or verbal prompting or help with
set-up.
4  Minimal assistance, requiring incidental hands-on help only (subject performs
>75% of the task).
3 Moderate assistance, subject still performs 50–75% of the task.
2  Maximal assistance, subject provides less than half of the effort (25–49%).
1  Total assistance, subject contributes <25% of the effort or is unable to do the task.
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Table 3
Rehabilitation program.
2/7/2012 A training in her upper/lower extremities joints range of
motion without pains (20 min)
2/9/2012 Low loaded resistance leg-training in the bed (15 min)
2/10/2012 3-m walking training with ﬁxed height walking frame (10 min)
2/14/2012 5-m walking using parallel bars (15 min)
2/17/2012 5–10-m crutch walking (20 min)
2/20/2012 20-m crutch walking (15 min) and paralyzed extremities joints
range of motion training (15 min)
3/1/2012 15-m crutch walking (15 min) and paralyzed extremities joints
range of motion training (15 min)
3/6/2012 Speech therapy (20 min)
4/4/2012 Discontinuation due to back pain
4/12/2012 Wheel chair training (20 min)
5/16/2012 Wheel chair training with ROM exercise and speech therapy
(30 min)
Furosemide     
Spironolactone 
Torasemide      
Azose mide 
Trichlor metiazi de 
100mg 
60mg 80mg 
62.5mg 50mg 50mg 
16mg 
 60 mg 
2mg 
0.5mg ig. 2. Chest X-ray on admission disclosed marked expansion of all right and left
rch, and lung ﬁelds were congested.
evel for four days before death, without inducing respiratory
epression. We  later received a letter of thanks from her family.
iscussion
We  often found it difﬁcult to explain the prognosis to end-
tage heart failure patients and their families. Repeated remissions
nd exacerbations, with patients occasionally overcoming acute
xacerbations, can make them optimistic [5]. Thus, healthcare
roviders must explain the prognosis with appropriate timing and
upport end-of-life preferences of patients and families. In Japan,
HF patients are usually hospitalized in general wards, and aggres-
ive procedures are continued until ineffectual. Patients and family
embers therefore ﬁnally face inevitable end-of-life situations,
nd are often not prepared for death. Most in-patients with severe
HF have not consulted physicians about cardiopulmonary resus-
itation and there are differences of opinion between patients
nd physicians [6]. Prognosis is a sensitive topic for patients and
Time course 2012.2 2012.3 2012.4 2012.5 2012.6 2012.7 
Fig. 4. Time course of diuretics usage.
Fig. 3. Electrocardiogram revealed sinus tachycardia and right axis deviation. II, III, aVF, V1, and V2 leads showed strain type T wave inversion.
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dig. 5. Continuous intravenous infusion of morphine via a syringe pump was start
RS,  numeric rating scale [19].
amilies. Therefore, physicians should fully explain therapeutic
trategies for end-stage CHF while the condition remains stable,
llowing patients and families to specify types of care desired and
omfort measures. Practically, it is not exceptional to provide pal-
iative care for patients with end-stage heart failure. This process
ould ultimately help satisfy end-of-life patients and families as
ell.
Another medical issue is the change in the medical care system
n Japan. More speciﬁcally, medical care should have continuity,
.e. acute/sub-acute stage beds, and chronic care beds in hospi-
als, followed by nursing homes, residential services, and at-home
ervices. Moreover, hospitals should strengthen their capacity to
eceive patient referrals who have substantial needs for medical
reatment from acute stage. In particular, end-of-life patients and
heir families can place great conﬁdence in continuity of tangible
nformation about medical care. Thus, consistency of explanations
nd treatment approaches is ensured, being potentially reassur-
ng to end-of-life patients and their families. It is important to
rovide continuity of tangible information to patients. Thus, we
ealthcare providers record explanations in a notebook for heart
ailure patients published by the Regional Health Care Council of
iroshima Prefecture. Patients are advised to carry it to promote
arly initiation of rehabilitation therapy, community cooperation,
nd support at discharge. In caring for end-stage CHF, serious
onsideration must be given to treatment choices focusing not
nly on improving outcomes but also quality of life and pro-
ision of tailor-made explanations to obtain informed consent,
s in advanced cancer cases. To improve palliative care for CHF
ith repeated abrupt exacerbations and remissions, as compared
ith other diseases during the end-of-life period, it is essen-
ial to communicate between various healthcare providers and
atients and to maintain good partnerships with families until
eath.
Various symptoms can be problematic for end-stage CHF
atients, with respiratory distress being common and causing
igniﬁcant suffering [7,8]. Intense pain, dyspnea, and distress
ay  occur for three days before death [9]. In our patient, opioids
elieved symptoms for her ﬁnal four days. Analgesia with opi-
ids and sedation with diazepam and midazolam are reportedly
seful for eliminating the discomfort [10]. Diuretics, used for the
reatment of heart failure, are effective in relieving respiratory
istress due to over-hydration. Ventilation–perfusion mismatchthe optimized doses for pain alleviation determined by a palliative care specialist.
and atrophy of respiratory muscles are involved in respiratory
distress, although the mechanisms are not understood [11].
Diuretics and non-pharmacological therapies including salt and/or
water restriction are effective for respiratory distress. However,
respiratory distress is difﬁcult to control in end-stage CHF patients
even with these treatments.
Opioids relieve respiratory symptoms of cancer patients. In the
USA and Europe, opioids are advocated for pain control in end-of-
life CHF care [12]. In Japan, where terminal care for patients with
end-stage CHF is being recognized by the general public, pain relief
and sedation are controversial [13]. There are no large clinical stud-
ies on opioids for CHF, but a few randomized controlled studies
demonstrated opioid efﬁcacy [14]. Indeed, two-thirds of patients
with advanced heart failure have been reported to have severe pain
[15]. So we  need to initiate opioid use, when end-stage patients feel
refractory pain or dyspnea.
The mechanism of action involves vasodilatation and effects
on lung and brain respiratory receptors. Adverse effects of opi-
oids include bradycardia, hypotension, and respiratory depression.
Dosage adjustment is absolutely required. Even low-dose opioids
reportedly relieve respiratory distress, making them an important
option for treating intractable respiratory distress in patients with
end-stage CHF [16].
Hospice care is becoming increasingly important, but non-
cancer patients rarely receive it in Japan. However, hospice can
be an option for end-stage CHF patients to spend their ﬁnal days
with relief of pain, symptoms, and mental distress [17]. Trans-
fer to hospice is preferred for patients with severe psychological
symptoms or needing expert healthcare and opioids. We  need to
ensure that we can provide palliative care in hospice, whoever
needs it in the near future. Another study [18] demonstrated the
number of patients dying at a hospice and the percentage who
obtained palliative care to be lower in CHF than in cancer patients.
Regarding end-of-life care outside medical facilities, patients may
die at home if they can receive palliative care supervised by a
qualiﬁed expert. However, CHF patients have complex problems
different from those of other diseases [19]. Our patient was  able
to spend her last 72 h free of distress with opioid administration
at a stable dose. Our experience with this case conﬁrms previ-
ous results demonstrating that opioids can be used safely and
effectively for relieving symptoms during end-of-life heart failure
[20].
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Heart-failure hospice is potentially a place to die for end-of-life
HF patients, attended by their families and healthcare providers.
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